In this file
Cancelling MEDVi can mean stopping a future membership payment, halting an unfilled prescription, or asking for money back on a longer commitment. State which action you want instead of assuming one request does everything.
A useful cancellation record includes the plan you accepted, the next payment date, and the current order stage. The policy information below is a starting point for that record; only the applicable agreement and the provider’s response can settle a particular transaction.
What the provider documents say
MEDVi provides links to legal and refund material, but not every legal destination could be established from the accessible evidence. Obtain the actual terms for the offer. Do not infer a refund right from a review, a guarantee headline, or an unanswered cancellation message.
The captured weight-loss material did not support one dependable all-in current price for every MEDVi plan. Its QUAD per-dose advertising concerns a different product category. For weight management, request the named medication, supply period, care charges, and the amount taken at renewal.
Find the stage your request has reached
Before payment, ask for the agreement and any charge that may remain after an unsuccessful clinical assessment. After payment but before pharmacy submission, ask whether the order can be stopped and whether a clinical or processing fee is retained.
Once medication has been prepared or shipped, prescription-return restrictions can be different from membership-renewal rules. Do not assume a cancellation button reverses a pharmacy transaction that has already occurred. A refund request should name the payment and explain the basis under the policy.
Send a clear request
The published telephone number for MEDVi is (323) 690-1564. An email route appears at help@medvi.org.
A concise request could say: ‘Please stop future renewals for my MEDVi plan and confirm the effective date. Please also confirm whether order [reference] has reached the pharmacy. I am separately requesting review of [charge] under the cancellation or refund terms I accepted.’ Fill in your own details through the provider’s secure channel.
Plan the care transition
The public partner list includes Triad Rx, Red Rock, and Beaker. That list is a lead for questions, rather than confirmation of the pharmacy selected for a patient. The assigned dispenser and formulation still need to be identified.
Tell the clinician if access, side effects, affordability, or another medical concern is the reason for stopping. Cancelling payments does not provide instructions for stopping or restarting a prescription. If moving to another service, the new professional should review the treatment history before making a prescribing decision.
Keep the useful evidence
Retain the original terms, receipt, renewal notice, dated request, and the provider’s response. If another payment occurs, those records help distinguish an administrative mistake from a remaining contractual obligation.
If a charge is disputed, first identify the charging company and the service it represents. A platform, pharmacy, clinician, or financing provider may use a different statement description. Ask the relevant company to explain the charge rather than treating every unfamiliar name as proof of fraud.
Read the connected files
The MEDVi provider file connects the cost details, support routes, and cancellation questions so that the same plan can be checked from more than one angle.
For a broader explanation of renewals, prepaid periods, and order-stage restrictions, see subscriptions and refund questions.
Source notes
Provider material describes the company’s own offer. Official medical references explain clinical and regulatory context; they do not endorse this publication or its commercial partner.
- MEDVi: provider, pharmacy, and contact disclosures ↗Provider-published information · Checked September 22, 2026
- FDA: MEDVi warning letter, February 20, 2026 ↗Regulatory / public agency · Checked September 22, 2026
- MEDVi QUAD: product and ingredient page ↗Provider-published information · Checked September 22, 2026
- FDA: concerns with unapproved GLP-1 drugs ↗Regulatory / public agency · Checked September 22, 2026